聖湘生物(688289.SH)2020年淨利大增65倍至26.17億元 年報推10派3.75元
格隆匯3月29日丨聖湘生物(688289.SH)披露2020年年度報吿,報吿期內,公司實現營業收入47.63億元,同比增長1203.53%;歸屬於母公司的淨利潤26.17億元,同比增長6527.90%;基本每股收益7.01元;年報推10派3.75元,加上三季報每10股派息7.5元,全年合計每10股派息11.25元。
報吿期內,公司秉承“普惠基因科技,造福百姓健康”的理念,圍繞戰略發展規劃方向,聚焦科技抗疫和重大疾病防控體系建設,服務全民健康事業,穩步有序地推進研發、技術、質量、產品、市場、渠道、服務等各項工作,產品收入和利潤均實現持續增長,公司主營業務繼續呈現良好發展態勢。
報吿期內,公司研發投入持續加強,研發費用達到8,277.13萬元,較上年研發支出增長112.48%。截至報吿期末,公司擁有研發人員313人,佔公司總人數的34.36%。研發人員的專業領域涵蓋了分子生物學、細胞生物學、免疫學、病理學、藥理學、遺傳學、臨牀檢驗學、自動化控制等多個領域,打造了一支跨學科的複合型研發團隊。
報吿期內,公司新獲國內外產品註冊准入100個,其中境外註冊准入90個;新增國內外專利授權33項,其中國內發明專利授權18項;參與制定國內外行業標準6項,其中國際標準1項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.